Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
18.84
-0.07 (-0.37%)
Jan 21, 2026, 4:00 PM EST - Market closed
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
$236,292
Profits / Employee
-$110,654
Market Cap
2.10B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | 1,194 | 502 | 72.54% | 1,194 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZLAB News
- 8 days ago - Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 8 days ago - Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 15 days ago - Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - Business Wire
- 16 days ago - Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
- 6 weeks ago - Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis - Business Wire
- 6 weeks ago - Zai Lab Announces Updates to China's National Reimbursement Drug List - Business Wire
- 2 months ago - Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy) - Seeking Alpha